Is Planet Labs (PL) Ready for Primetime as it Goes Public via DMYQ?

by | Nov 24, 2021

Earth Data company Planet Labs is going public thru dMY Technology IV (DMYQ) via a SPAC transaction. Founder and CEO Will Marshall, CFO Ashley Johnson, and dMY CEO Niccolo de Masi join us on the podcast to discuss Planet’s prospects and the SPAC transaction. 

Planet touts itself as the only company in the world that has the ability to do full daily earth scans, sometimes even twice a day. One can think of Planet as the “Bloomberg Terminal” for Earth data – allowing the consumer to consume their satellite imagery via their own computers. Planet serves numerous industry verticals and has aims for much more, and operates on a data subscription business model. 

Key Takeaways:

  • Not a “satellite company” –> Planet owns the raw satellite data that enables Planet and customers to create value-add data/analytics/services on top
  • De-risked technology (i.e. launched 200 satellites) and product-market fit (i.e. $100m revenue / +700 customers)
  • Subscription data business w/ strong renewal rates and account growth
  • Google partnership — Google outsources to them, sold their satellites to Planet, and now sells a bundle of Planet + Google Cloud
  • Capital raised will enable sales and marketing — team believes this is the key limiter on growth at this point
  • Product led by Kevin Weil –> previously at Facebook, Instagram, and Twitter
  • Strong, serial sponsor in dMY Technology

Boardroom Alpha’s SPAC Service
For ongoing tracking, analytics, and data on SPACs checkout Boardroom Alpha’s SPAC Data and Analytics service.

<a href="https://www.boardroomalpha.com/author/draps/" target="_self">David Drapkin</a>

David Drapkin

Spent his formative years at Goldman Sachs and now embraces the start-up life in NYC. A long suffering Oakland (Las Vegas) Raiders fan and graduate of the Wharton School at the University of Pennsylvania. Semi-professional go-kart racer waiting for his shot.

Know Who Drives Return

Objective, data-driven assessments for every public company director and officer.

Learn More

SPAC Analytics & Database

Comprehensive research and analytics on every SPAC, sponsor, and deal. Real-time alerts, yields, red flags, filings, investors, and much more. API access to institutional grade SPAC database.

Learn More

Monthly SPAC Review

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

SPAC Research & Analysis

MSP Recovery Debuts Tomorrow

May 23, 2022

Medicare and Medicaid secondary payer reimbursement recovery specialist MSP Recovery (MSPR) begins trading tomorrow. Extension for TINV/Grindr. And the rest of the day’s news in SPACs.

Comera Life Sciences Debuts in the Red

May 20, 2022

Comera Life Sciences (CMRA), the maker of self-injectible biologics, deSPAC’d today, closing down 9%. An updated look at deSPAC count and redemption rates. And the rest of the day’s news in SPACs.

SPAC Deals on a Daily Double

May 19, 2022

Another 2 SPAC DAs today, offset by some liquidations. And the rest of the day’s news in SPACs.

Starting the Week with 2 DAs

May 16, 2022

Starting the week off with 2 DAs– oil & gas and battery tech. And the rest of the day’s news in SPACs.

Know Who Drives Return Podcast

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.